IPO registrations (S-1, F-1) · Registrants
APPLIED GENETIC TECHNOLOGIES CORP
- SEC CIK
- 1273636 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2014-01-10, last 2020-02-05; 3 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2014-03-27; declared effective 2014-03-26
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 14193 NW 119TH TERRACE, SUITE #10, Alachua, FL 32615
- EIN
- 59-3553710
- EDGAR entity type
- operating
- Insiders and CEO pay
- APPLIED GENETIC TECHNOLOGIES CORP on the corporate pages
Offering terms
- Proposed price range
- $13.00–$15.00 per share (S-1/A filed 2014-03-12)
- Final price
- $12.00 per share, below the range (424B4 filed 2014-03-27, an initial public offering)
- Shares sold
- 4,166,667
- Gross proceeds
- $50,000,004 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol AGTC
- Lead underwriters
- BMO Capital Markets; Wedbush Securities
- Syndicate
- Cantor Fitzgerald; Roth Capital Partners
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: APPLIED GENETIC TECHNOLOGIES CORPORATION EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: BEACON THERAPEUTICS (USA), INC. EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: BEACON THERAPEUTICS (USA), INC. EXACT (EIN (EXACT))
- Federal award recipient: APPLIED GENETIC TECHNOLOGIES CORPORATION Fuzzy (name and state)
- SEC filer: APPLIED GENETIC TECHNOLOGIES CORP EXACT (CIK (EXACT))
Filings 16
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-01-10 | S-1 | S-1 (registration) | APPLIED GENETIC TECHNOLOGIES CORP | 0001193125-14-008046 ↗ |
| 2014-03-04 | S-1/A | S-1/A (amendment) | APPLIED GENETIC TECHNOLOGIES CORP | 0001193125-14-082527 ↗ |
| 2014-03-12 | S-1/A | S-1/A (amendment) | APPLIED GENETIC TECHNOLOGIES CORP | 0001193125-14-094588 ↗ |
| 2014-03-26 | EFFECT | EFFECT (declared effective) | APPLIED GENETIC TECHNOLOGIES CORP | 9999999995-14-000777 ↗ |
| 2014-03-27 | 424B4 | 424B4 (final prospectus) | APPLIED GENETIC TECHNOLOGIES CORP | 0001193125-14-118834 ↗ |
| 2014-07-11 | S-1 | S-1 (registration) | APPLIED GENETIC TECHNOLOGIES CORP | 0001193125-14-266668 ↗ |
| 2014-07-21 | S-1/A | S-1/A (amendment) | APPLIED GENETIC TECHNOLOGIES CORP | 0001193125-14-273802 ↗ |
| 2014-07-24 | EFFECT | EFFECT (declared effective) | APPLIED GENETIC TECHNOLOGIES CORP | 9999999995-14-002232 ↗ |
| 2014-07-25 | 424B4 | 424B4 (final prospectus) | APPLIED GENETIC TECHNOLOGIES CORP | 0001193125-14-280358 ↗ |
| 2015-05-20 | EFFECT | EFFECT (declared effective) | APPLIED GENETIC TECHNOLOGIES CORP | 9999999995-15-001415 ↗ |
| 2018-06-19 | EFFECT | EFFECT (declared effective) | APPLIED GENETIC TECHNOLOGIES CORP | 9999999995-18-001539 ↗ |
| 2020-01-29 | S-1 | S-1 (registration) | APPLIED GENETIC TECHNOLOGIES CORP | 0001193125-20-018614 ↗ |
| 2020-02-05 | S-1/A | S-1/A (amendment) | APPLIED GENETIC TECHNOLOGIES CORP | 0001193125-20-025421 ↗ |
| 2020-02-06 | EFFECT | EFFECT (declared effective) | APPLIED GENETIC TECHNOLOGIES CORP | 9999999995-20-000282 ↗ |
| 2020-02-07 | 424B4 | 424B4 (final prospectus) | APPLIED GENETIC TECHNOLOGIES CORP | 0001193125-20-028177 ↗ |
| 2021-04-12 | EFFECT | EFFECT (declared effective) | APPLIED GENETIC TECHNOLOGIES CORP | 9999999995-21-001401 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-03-12 | S-1/A | registration statement | $13.00–$15.00 | 3,571,000 | - | Nasdaq AGTC | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2014-03-27 | 424B4 | final prospectus | $12.00 | 4,166,667 | $50,000,004 | Nasdaq AGTC | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Alta Partners Management VIII, LLC | TenPercentOwner | 3 | 2014 | ||
| Alta Partners VIII, L.P. | TenPercentOwner | 3 | 2014 | ||
| BULLOCK LAWRENCE E | Officer | Chief Financial Officer | 7 | 2014–2017 | |
| Carroll Jill | Director,TenPercentOwner | 2 | 2014 | ||
| CASH HARVEY B | TenPercentOwner | 2 | 2014 | ||
| CHAMPSI FARAH | TenPercentOwner | 3 | 2014 | ||
| Chulay Jeffrey D. | Officer | See Remarks; VP and Chief Medical Officer; V.P. & Chief Medical Officer | 12 | 2014–2016 | |
| GIANOS PHILIP T | TenPercentOwner | 2 | 2014 | ||
| GLAXOSMITHKLINE PLC | Other; TenPercentOwner | 4 | 2014–2015 | ||
| Holmes W Stephen | TenPercentOwner | 2 | 2014 | ||
| HURWITZ EDWARD | Director | 13 | 2014–2022 | ||
| INTERWEST INVESTORS Q VIII LP | TenPercentOwner | 2 | 2014 | ||
| INTERWEST INVESTORS VIII L P | TenPercentOwner | 2 | 2014 | ||
| InterWest Management Partners VIII, LLC | TenPercentOwner | 2 | 2014 | ||
| INTERWEST PARTNERS VIII LP | TenPercentOwner | 2 | 2014 | ||
| JANNEY DANIEL | TenPercentOwner | 3 | 2014 | ||
| Kliman Gilbert H | TenPercentOwner | 2 | 2014 | ||
| Knop David R. | Officer | Director, Process Development | 3 | 2014 | |
| Koenig Scott | Director | 12 | 2014–2022 | ||
| MedImmune Ventures, Inc. | TenPercentOwner | 2 | 2014 | ||
| Menichella Daniel L | Officer | V.P. & Chief Business Officer | 5 | 2014–2015 | |
| NOHRA GUY P | TenPercentOwner | 3 | 2014 | ||
| ORONSKY ARNOLD L | Director; Director,TenPercentOwner | 6 | 2014–2017 | ||
| Rosen James | Director; Director,TenPercentOwner | 13 | 2014–2022 | ||
| Washer Susan B. | Director,Officer | President and CEO; President & CEO; See Remarks | 17 | 2014–2022 | |
| Wu Samuel | Director,TenPercentOwner | 2 | 2014 | ||
| Magovcevic Ivana | Director | 12 | 2014–2021 | ||
| GUYER DAVID R | Director | 1 | 2014 | ||
| Potter Stephen W | Officer | Chief Business Officer; See Remarks; VP and Chief Business Officer | 17 | 2015–2022 | |
| PEACOCK BRUCE | Director | 3 | 2015 | ||
| Shearman Mark S | Officer | Chief Scientific Officer | 12 | 2015–2020 | |
| VANLENT ANNE | Director | 10 | 2016–2022 | ||
| Goldstein Michael H. | Officer | Chief Medical Officer | 3 | 2016–2017 | |
| Ashe Andrew D. | Officer | General Counsel | 2 | 2017 | |
| Sullivan William A. | Officer | Chief Financial Officer | 6 | 2017–2020 | |
| Feinsod Matthew | Officer | Exec. VP, Global Strat. & Dev.; Interim Chief Medical Officer | 29 | 2017–2019 | |
| Aliski William | Director | 8 | 2018–2022 | ||
| Krex Brian | Director,Officer; Officer | General Counsel | 4 | 2019 | |
| Heah Theresa | Officer | Chief Medical Officer | 2 | 2019 | |
| Inspirational Visions B.V. | TenPercentOwner | 3 | 2019 | ||
| Krol Patrick Johan Hendrik | TenPercentOwner | 3 | 2019 | ||
| Privium Fund Management B.V. | TenPercentOwner | 3 | 2019 | ||
| Stichting Aescap 2.0 | TenPercentOwner | 3 | 2019 | ||
| Reynolds Gerald Anthony | Officer | Chief Accounting Officer | 5 | 2021–2022 | |
| Hashad Yehia | Director | 4 | 2021–2022 | ||
| Lieber Jonathan I | Officer | Chief Financial Officer | 4 | 2021–2022 | |
| Schneider Susan | Officer | Chief Medical Officer | 4 | 2021–2022 | |
| Robinson James A. Jr. | Director | 3 | 2021–2022 | ||
| Scaria Abraham | Officer | Chief Scientific Officer | 4 | 2021–2022 | |
| DOyley-Gay Hope | Officer | General Counsel | 4 | 2021–2022 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | APPLIED GENETIC TECHNOLOGIES CORPORATION | FL | State business registries | name and state |
| Plan sponsor | BEACON THERAPEUTICS (USA), INC. | MA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Federal award recipient | APPLIED GENETIC TECHNOLOGIES CORPORATION | FL | Federal spending (USAspending) | name and state |
| Patent assignee | Applied Genetic Technologies Corporation | FL | Patents (USPTO) | name and state |
| SEC filer | APPLIED GENETIC TECHNOLOGIES CORP | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Applied Genetic Technologies Corporation | FL | Trademarks (USPTO) | name and state |
| Business registration | BEACON THERAPEUTICS (USA), INC. | State business registries | EIN (EXACT, as the state registration reports it) | |
| Form 5500 plan sponsor | BEACON THERAPEUTICS (USA), INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.